Every dose figure in the Hexarelin literature comes from a research protocol with monitoring and a defined endpoint, not from an approved label, because no regulator has ever approved the compound for human use. Published studies scaled amounts to body weight in micrograms per kilogram and delivered them most often by subcutaneous or intravenous injection, with intranasal and oral routes examined less often. The reported numbers describe what investigators did and measured, and they carry no implication of a safe or effective dose outside that setting.
Hexarelin holds no approved human indication in the United States or Europe, and the dosing figures reported in its literature are weight-scaled research amounts, commonly expressed in micrograms per kilogram and given by subcutaneous or intravenous injection.
The published amounts are weight-scaled probes of a hormonal response, which is why they resist translation into a schedule. Acute human work used single injections in the low microgram-per-kilogram range to trigger a measurable growth hormone pulse, and it ran into a ceiling: past a certain point, more peptide bought little additional hormone.
Acute Hexarelin studies expressed single doses in micrograms per kilogram of body weight and reported a ceiling effect, where growth hormone output plateaued rather than rising with further increases in dose.
Most peptide secretagogues appear in the literature by injection alone. Hexarelin is the unusual case, since researchers documented real activity through the nose and by mouth as well, with bioavailability falling at each step away from the needle. Route tracked the study's question: work timing a peak used intravenous delivery, while work modeling repeated exposure leaned on subcutaneous or the alternative routes.
Hexarelin retained measurable activity by intranasal and oral administration and not only by injection, though reported bioavailability declined at each route away from intravenous delivery, and human studies concentrated on the injectable and intranasal forms.
The freeze-dried form exists for a practical reason: dry peptide survives shipping and long storage in a way a solution does not. Once a lab reconstitutes it the clock starts, and the handling described in the literature is mostly about slowing a degradation that begins the moment water is added.
Lyophilized Hexarelin tolerates refrigeration or freezing for extended periods in its dry form, while a reconstituted solution degrades through hydrolysis and oxidation and is described in the literature as short-lived, kept cold and protected from light.
A fixed daily amount does not keep producing the same growth hormone surge, and that is not a quirk of the reports but the pharmacology. Hexarelin acts on the growth hormone secretagogue receptor, the same receptor ghrelin targets, and repeated stimulation drives that receptor toward a less responsive state through internalization and reduced signaling efficiency. The consequence running through the literature is that a long uninterrupted course is self-limiting, because the response it produces fades on its own.
Repeated Hexarelin exposure drives growth hormone secretagogue receptor desensitization that studies observed developing over days to a few weeks of sustained administration and that a washout period partly reversed.
When a dose landed mattered nearly as much as its size, because Hexarelin acted against whatever hormonal state the body was already in. Research reports therefore specify the conditions and the clock around an amount, not the amount alone.
Elevated blood glucose and circulating fatty acids following a meal blunt growth hormone release, which is why studies seeking a maximal Hexarelin response administered the peptide in a fasted state.
The safety record is defined as much by the gap in it as by what was observed. Hexarelin never completed the clinical development that would characterize risk over months and years, so no long-term human data exists to weigh against the short-term findings. What the trials did capture is that its effects reach past growth hormone, into cortisol, prolactin, cardiac tissue, and glucose handling.
Hexarelin elevated cortisol and prolactin alongside growth hormone in published studies, and no long-term human safety data exists because the compound never completed full clinical development.
Among injectable peptide secretagogues, Hexarelin is documented as one of the more potent, producing a strong growth hormone response at microgram amounts comparable to or lower than GHRP-6 and GHRP-2. Potency is not the whole ledger, since the same literature reports it as less selective and faster to desensitize than its peers. Against an orally active agent like MK-677 the contrast is format and duration rather than raw strength, as that compound is taken by mouth and sustains hormone levels across a long half-life while Hexarelin is injected and acts in sharp pulses.
| Criteria | Hexarelin | GHRP-2 / GHRP-6 | Ipamorelin |
|---|---|---|---|
| Relative potency | Higher | Lower | Lower |
| Cortisol and prolactin spillover | Reported | Reported | Minimal by design |
| Desensitization with sustained use | Pronounced | Present | Present |
| Approved human indication | None | None | None |
Ipamorelin, not Hexarelin, is the secretagogue the literature describes as designed to release growth hormone with minimal disturbance to cortisol and prolactin, while Hexarelin is reported as the more potent of the two and the faster to desensitize, and neither carries an approved human indication.
Research use only is not a marketing flourish on a Hexarelin vial, it is a legal boundary. The label marks material intended for laboratory investigation by qualified researchers rather than for administration to people, and marketing it for human consumption places a seller outside the law.
Hexarelin holds no approved therapeutic indication from any major drug regulator, is sold and labeled for research use only, and is prohibited at all times in sanctioned sport by anti-doping authorities.
Educational use only. This article describes what the published scientific and clinical literature reports about Hexarelin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
